Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo

References

• Linthorst Homan MW, Spuls PI, de Korte J, et al. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol. 2009;61(3):411–420. doi:10.1016/j.jaad.2009.03.02219577331
   PubMed Web of Science ®Google Scholar
• Guerra L, Dellambra E, Brescia S, Raskovic D. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab. 2010;11:451–467. doi:10.2174/13892001079152610520540698
   PubMed Web of Science ®Google Scholar
• Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28:85–92. doi:10.1080/13543784.2019.1551358
   PubMed Web of Science ®Google Scholar
• Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19:5662–5679. doi:10.1038/sj.onc.120392511114747
   PubMed Web of Science ®Google Scholar
• Cheh X, Vinkemeier U, Zhao Y, et al. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell. 1998;93:827–839.9630226
   PubMed Web of Science ®Google Scholar
• Grimes PE. New insights and new therapies in vitiligo. JAMA. 2005;293:730–735. doi:10.1001/jama.293.6.73015701915
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328. doi:10.1146/annurev-med-051113-02453725587654
   PubMed Web of Science ®Google Scholar
• Ghoreschi K1, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib. J Immunol. 2011;186:4234–4243. doi:10.4049/jimmunol.100366821383241
   PubMed Web of Science ®Google Scholar
• Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677–683. doi:10.1001/archderm.140.6.67715210457
   PubMedGoogle Scholar
• Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol Venereol Leprol. 2006;72(4):315–321.16880586
   PubMedGoogle Scholar
• Aslanian F, Noe R, Antelo D, et al. Immunohistochemical findings in active vitiligo including depigmenting lesions and non-lesional skin. Open Dermatol J. 2008;2:105–110. doi:10.2174/1874372200802010105
   Google Scholar
• Alves De Medeiros AK, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;16:1–16.
   Google Scholar
• Bilalovic N. Sandstad B and Torlakovic E. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol. 2004;17:1251–1258. doi:10.1038/modpathol.380017415205682
   PubMed Web of Science ®Google Scholar
• Wen X, Hamblin MR, Xian Y, et al. A preliminary study of fractional CO2 laser added to topical tacrolimus combined with 308 nm excimer lamp for refractory vitiligo. Dermatol Ther. 2018;32:e12747.30238584
   PubMed Web of Science ®Google Scholar
• Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65:473–491. doi:10.1016/j.jaad.2010.11.06121839315
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36. doi:10.1038/nrrheum.2015.16726633291
   PubMed Web of Science ®Google Scholar
• Rashighi M, Harris JE. Interfering with the IFN-gamma/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med. 2015;3:343.26734651
   PubMed Web of Science ®Google Scholar
• Moretti S, Fabbri O, Baroni G, et al. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenviroment and correlation to keratinocyte apoptosis. Histol Histopathol. 2009;24:849–857. doi:10.14670/HH-24.84919475531
   PubMed Web of Science ®Google Scholar
• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736–744. doi:10.1016/j.jaad.2016.12.00528139263
   PubMed Web of Science ®Google Scholar
• King BA, Craiglow BG. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151:1110–1112. doi:10.1001/jamadermatol.2015.152026107994
   PubMed Web of Science ®Google Scholar
• Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74:370–371. doi:10.1016/j.jaad.2015.09.07326685721
   PubMed Web of Science ®Google Scholar
• Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76:1054–1060. doi:10.1016/j.jaad.2017.02.04928390737
   PubMed Web of Science ®Google Scholar
• Nada HR, El Sharkawy DA, Elmasry MF, Rashed LA, Mamdouh S. Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study. Arch Dermatol Res. 2018;310:39–46. doi:10.1007/s00403-017-1792-629127481
   PubMed Web of Science ®Google Scholar
• Hu K, Hou S, Li F, Xiang Q, Kijlstra A, Yang P. JAK1, but not JAK2 and STAT3, confers susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Han Chinese population. Invest Ophthalmol Vis Sci. 2013;54:3360–3365. doi:10.1167/iovs.13-1161523611997
   PubMed Web of Science ®Google Scholar
• Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77:1–13. doi:10.1016/j.jaad.2016.10.04828619550
   PubMed Web of Science ®Google Scholar
• Sander CS, Cooper SM, Ali I, Dean D, Thiele JJ, Wojnarowska F. Decreased antioxidant enzyme expression and increased oxidative damage in erosive lichen planus of the vulva. Bjog. 2005;112:1572–1575. doi:10.1111/j.1471-0528.2005.00743.x16225582
   PubMed Web of Science ®Google Scholar
• Tanemura A, Kotobuki Y, Itoi S, et al. Positive link between STAT3 activation and Th17 cell infiltration in vitiligo vulgaris. J Dermatol Sci. 2012;67:190–212. doi:10.1016/j.jdermsci.2012.05.00122682752
   PubMed Web of Science ®Google Scholar